Juan A Bueren

List of Publications by Year
in descending order

178	6,761	71102	74163
papers	citations	41 h-index	75 g-index

188	188	188	8302
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	<scp>CIBERER</scp>: Spanish national network for research on rare diseases: A highly productive collaborative initiative. Clinical Genetics, 2022, 101, 481-493.	2.0	9
2	Natural estrogens enhance the engraftment of human hematopoietic stem and progenitor cells in immunodeficient mice. Haematologica, 2021, 106, 1659-1670.	3.5	9
3	Generation of dyskeratosis congenita-like hematopoietic stem cells through the stable inhibition of DKC1. Stem Cell Research and Therapy, 2021, 12, 92.	5.5	0
4	Enhanced anti-inflammatory effects of mesenchymal stromal cells mediated by the transient ectopic expression of CXCR4 and IL10. Stem Cell Research and Therapy, 2021, 12, 124.	5.5	24
5	The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy. Frontiers in Cell and Developmental Biology, 2021, 9, 650664.	3.7	75
6	Natural gene therapy by reverse mosaicism leads to improved hematology in <scp>Fanconi</scp> anemia patients. American Journal of Hematology, 2021, 96, 989-999.	4.1	13
7	Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies. EBioMedicine, 2021, 69, 103427.	6.1	26
8	Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Molecular Therapy - Methods and Clinical Development, 2021, 22, 66-75.	4.1	10
9	Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment. Molecular Therapy - Methods and Clinical Development, 2021, 22, 350-359.	4.1	3
10	Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency. Molecular Therapy - Methods and Clinical Development, 2021, 22, 237-248.	4.1	11
11	Advances in the gene therapy of monogenic blood cell diseases. Clinical Genetics, 2020, 97, 89-102.	2.0	18
12	Targeted gene therapy into a safe harbor site in human hematopoietic progenitor cells. Gene Therapy, 2020, 27, 435-450.	4.5	3
13	Mosaicism in Fanconi anemia: concise review and evaluation of published cases with focus on clinical course of blood count normalization. Annals of Hematology, 2020, 99, 913-924.	1.8	26
14	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. Journal of Medical Genetics, 2020, 57, 258-268.	3.2	18
15	TALEN mediated gene editing in a mouse model of Fanconi anemia. Scientific Reports, 2020, 10, 6997.	3.3	3
16	Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemiaâ€“Related Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3044-3057.	7.0	23
17	Gene editing of PKLR gene in human hematopoietic progenitors through 5â€™ and 3â€™ UTR modified TALEN mRNA. PLoS ONE, 2019, 14, e0223775.	2.5	23
18	Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nature Medicine, 2019, 25, 1396-1401.	30.7	117

#	Article	IF	Citations
19	NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia. Cell Stem Cell, 2019, 25, 607-621.e7.	11.1	64
20	Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors. Molecular Therapy, 2018, 26, 1137-1153.	8.2	53
21	Leukocyte adhesion deficiency-I: A comprehensive review of all published cases. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1418-1420.e10.	3.8	85
22	Terapias avanzadas en enfermedades raras. Arbor, 2018, 194, 467.	0.3	1
23	Comparative Analysis between the In Vivo Biodistribution and Therapeutic Efficacy of Adipose-Derived Mesenchymal Stromal Cells Administered Intraperitoneally in Experimental Colitis. International Journal of Molecular Sciences, 2018, 19, 1853.	4.1	11
24	Advances in Gene Therapy for Fanconi Anemia. Human Gene Therapy, 2018, 29, 1114-1123.	2.7	31
25	Improved Hematopoietic Gene Therapy in a Mouse Model of Fanconi Anemia Mediated by Mesenchymal Stromal Cells. Human Gene Therapy, 2018, 29, 327-336.	2.7	11
26	Advances in the Gene Therapy of Patients with Fanconi Anemia. Blood, 2018, 132, 1022-1022.	1.4	4
27	Efficient CRISPR/Cas9-Mediated Gene Editing of Pklr in Human Hematopoietic Progenitors and Stem Cells for the Gene Therapy of Pyruvate Kinase Deficiency. Blood, 2018, 132, 5792-5792.	1.4	1
28	Preclinical Evaluation for the Gene Therapy of Patients with Leukocyte Adhesion Deficiency Type I. Blood, 2018, 132, 5798-5798.	1.4	0
29	In vivo imaging of lung inflammation with neutrophil-specific 68Ga nano-radiotracer. Scientific Reports, 2017, 7, 13242.	3.3	37
30	Therapeutic gene editing in <scp>CD</scp> 34 ⁺ hematopoietic progenitors from Fanconi anemia patients. EMBO Molecular Medicine, 2017, 9, 1574-1588.	6.9	54
31	A Short and Efficient Transduction Protocol for Mouse Hematopoietic Stem Cells with Lentiviral Vectors. Human Gene Therapy Methods, 2017, 28, 310-317.	2.1	2
32	Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients. Blood, 2017, 130, 1535-1542.	1.4	42
33	Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia. Blood Advances, 2017, 1, 319-329.	5.2	18
34	Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent. Blood Advances, 2017, 1, 2088-2104.	5.2	37
35	Intralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritis. Frontiers in Immunology, 2017, 8, 462.	4.8	27
36	Biodistribution and Efficacy of Human Adipose-Derived Mesenchymal Stem Cells Following Intranodal Administration in Experimental Colitis. Frontiers in Immunology, 2017, 8, 638.	4.8	18

#	Article	IF	Citations
37	Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. Current Gene Therapy, 2017, 16, 338-348.	2.0	31
38	TGF-Î²: a master regulator of the bone marrow failure puzzle in Fanconi anemia. Stem Cell Investigation, 2016, 3, 75-75.	3.0	5
39	228. Characterization of Hematopoietic Progenitors from Pyruvate Kinase Deficient (PKD) Patients and Transduction of PKD CD34+ Cells with a Therapeutic Lentiviral Vector. Molecular Therapy, 2016, 24, S89.	8.2	0
40	558. Targeted Gene Therapy in CD34+ Cells from Healthy Donors and Fanconi Anemia Patients. Molecular Therapy, 2016, 24, S223.	8.2	0
41	753. Lentiviral-Mediated Gene Correction of Mobilized Peripheral Blood Progenitors and Repopulating Cells from FA-A Patients. Molecular Therapy, 2016, 24, S297-S298.	8.2	0
42	Lentiviral Vector-Mediated Correction of a Mouse Model of Leukocyte Adhesion Deficiency Type I. Human Gene Therapy, 2016, 27, 668-678.	2.7	21
43	Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency. Molecular Therapy, 2016, 24, 1187-1198.	8.2	55
44	Adiposeâ€derived mesenchymal stromal cells modulate experimental autoimmune arthritis by inducing an early regulatory innate cell signature. Immunity, Inflammation and Disease, 2016, 4, 213-224.	2.7	24
45	Longâ€term skin regeneration in xenografts from <scp>iPSC</scp> teratomaâ€derived human keratinocytes. Experimental Dermatology, 2016, 25, 736-738.	2.9	4
46	Direct Conversion of Fibroblasts to Megakaryocyte Progenitors. Cell Reports, 2016, 17, 671-683.	6.4	31
47	Gene Editing of the Human Pklr Gene in Human Hematopoietic Progenitors to Correct Pyruvate Kinase Deficiency. Blood, 2016, 128, 3513-3513.	1.4	1
48	Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells. Stem Cell Reports, 2015, 5, 1053-1066.	4.8	32
49	Mesenchymal stromal cells enhance the engraftment of hematopoietic stem cells in an autologous mouse transplantation model. Stem Cell Research and Therapy, 2015, 6, 165.	5.5	44
50	Human Adipose-Derived Mesenchymal Stem Cells Modulate Experimental Autoimmune Arthritis by Modifying Early Adaptive T Cell Responses. Stem Cells, 2015, 33, 3493-3503.	3.2	65
51	<scp>BCRâ€“JAK2</scp> drives a myeloproliferative neoplasm in transplanted mice. Journal of Pathology, 2015, 236, 219-228.	4.5	3
52	Phase I/II Gene Therapy Trial of Fanconi Anemia Patients with a New Orphan Drug Consisting of a Lentiviral Vector Carrying the FANCA Gene: A Coordinated International Action (EuroFancolen). Human Gene Therapy Clinical Development, 2015, 26, 81-82.	3.1	2
53	Perspectives on gene therapy for Fanconi anemia. Expert Opinion on Orphan Drugs, 2015, 3, 899-910.	0.8	1
54	Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential. PLoS ONE, 2015, 10, e0139740.	2.5	8

#	Article	IF	Citations
55	Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs. Current Gene Therapy, 2015, 15, 550-562.	2.0	23
56	Development of a Web Course on Gene Therapy by the International Consortium of Gene Therapy. Molecular Therapy, 2014, 22, 482.	8.2	0
57	Targeted gene therapy and cell reprogramming in <scp>F</scp>anconi anemia. EMBO Molecular Medicine, 2014, 6, 835-848.	6.9	66
58	Generation of iPSCs from Genetically Corrected Brca2 Hypomorphic Cells: Implications in Cell Reprogramming and Stem Cell Therapy. Stem Cells, 2014, 32, 436-446.	3.2	15
59	Brief Report: Reduced Expression of CD18 Leads to the In Vivo Expansion of Hematopoietic Stem Cells in Mouse Bone Marrow. Stem Cells, 2014, 32, 2794-2798.	3.2	13
60	Conversion of Human Fibroblasts Into Monocyte-Like Progenitor Cells. Stem Cells, 2014, 32, 2923-2938.	3.2	40
61	Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs. Nature Communications, 2014, 5, 4330.	12.8	102
62	Mesenchymal stromal cells enhance hematopoietic engraftment in a mouse model of autologous transplantation with high risk of engraftment failure. Cytotherapy, 2014, 16, S11-S12.	0.7	1
63	Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases. Molecular Therapy, 2013, 21, 266-268.	8.2	12
64	Mutations in ERCC4, Encoding the DNA-Repair Endonuclease XPF, Cause Fanconi Anemia. American Journal of Human Genetics, 2013, 92, 800-806.	6.2	272
65	Brief Report: Impaired Cell Reprogramming in Nonhomologous End Joining Deficient Cells. Stem Cells, 2013, 31, 1726-1730.	3.2	14
66	Inhibitory effects of marineâ€derived DNAâ€binding antiâ€tumour tetrahydroisoquinolines on the Fanconi anaemia pathway. British Journal of Pharmacology, 2013, 170, 871-882.	5.4	9
67	Reduced Efficacy of Mesenchymal Stromal Cells in Preventing Graft-Versus-Host Disease in an in Vivo Model of Haploidentical Bone Marrow Transplant with Leukemia. Cell Transplantation, 2013, 22, 1381-1394.	2.5	6
68	Epigenetic Alterations In Fanconi Anemia: Role In Disease Progression and Therapeutic Potential. Blood, 2013, 122, 4865-4865.	1.4	0
69	Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNFÎ± regulation and proliferation of hematopoietic progenitor cells. Blood, 2012, 119, 3042-3049.	1.4	23
70	A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. Blood, 2012, 119, 1139-1150.	1.4	41
71	Unraveling the role of FANCD2 in chronic myeloid leukemia. Leukemia, 2012, 26, 1447-1448.	7.2	1
72	Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosine-Kinase. PLoS ONE, 2012, 7, e32451.	2.5	27

#	Article	IF	Citations
73	Correction of SCID-X1 Using an EnhancerlessVavPromoter. Human Gene Therapy, 2011, 22, 263-270.	2.7	12
74	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	5.0	23
75	Generation of Functional Neutrophils from a Mouse Model of X-Linked Chronic Granulomatous Disorder Using Induced Pluripotent Stem Cells. PLoS ONE, 2011, 6, e17565.	2.5	21
76	Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood, 2011, 117, 3759-3769.	1.4	108
77	Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact. Journal of Medical Genetics, 2011, 48, 242-250.	3.2	51
78	Fanconi anaemia: from a monogenic disease to sporadic cancer. Clinical and Translational Oncology, 2011, 13, 215-221.	2.4	19
79	Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. Molecular Therapy, 2011, 19, 1193-1198.	8.2	45
80	Biochemical Correction of X-CGD by a Novel Chimeric Promoter Regulating High Levels of Transgene Expression in Myeloid Cells. Molecular Therapy, 2011, 19, 122-132.	8.2	141
81	Immunoresponse against the transgene limits hematopoietic engraftment of mice transplanted in utero with virally transduced fetal liver. Gene Therapy, 2011, 18, 469-478.	4.5	3
82	Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Experimental Cell Research, 2010, 316, 3109-3123.	2.6	171
83	A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. Nature Protocols, 2010, 5, 647-660.	12.0	52
84	Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells. PLoS ONE, 2010, 5, e15525.	2.5	20
85	Development of Lentiviral Vectors with Optimized Transcriptional Activity for the Gene Therapy of Patients with Fanconi Anemia. Human Gene Therapy, 2010, 21, 623-630.	2.7	43
86	In Vivo Delivery of Antigens by Adenovirus Dodecahedron Induces Cellular and Humoral Immune Responses to Elicit Antitumor Immunity. Molecular Therapy, 2010, 18, 1046-1053.	8.2	30
87	Mesenchymal stem cells: biological properties and clinical applications. Expert Opinion on Biological Therapy, 2010, 10, 1453-1468.	3.1	147
88	Development of an in vitro model for the simultaneous study of the efficacy and hematotoxicity of antileukemic compounds. Toxicology Letters, 2010, 199, 317-322.	0.8	5
89	Increased Intraocular Insulin-like Growth Factor-I Triggers Blood-Retinal Barrier Breakdown. Journal of Biological Chemistry, 2009, 284, 22961-22969.	3.4	57
90	Lentiviral-mediated Genetic Correction of Hematopoietic and Mesenchymal Progenitor Cells From Fanconi Anemia Patients. Molecular Therapy, 2009, 17, 1083-1092.	8.2	44

#	Article	IF	Citations
91	Rescue of Pyruvate Kinase Deficiency in Mice by Gene Therapy Using the Human Isoenzyme. Molecular Therapy, 2009, 17, 2000-2009.	8.2	31
92	Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors. Molecular Therapy, 2009, 17, 1919-1928.	8.2	337
93	In vitro sensitivity of granulo-monocytic progenitors as a new toxicological cell system and endpoint in the ACuteTox Project. Toxicology and Applied Pharmacology, 2009, 238, 111-119.	2.8	10
94	Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature, 2009, 460, 53-59.	27.8	660
95	Immunomagnetic Enrichment of Human and Mouse Hematopoietic Stem Cells for Gene Therapy Applications. Methods in Molecular Biology, 2009, 506, 1-11.	0.9	1
96	Bone Marrow-Derived Cells Promote Liver Regeneration in Mice With Erythropoietic Protoporphyria. Transplantation, 2009, 88, 1332-1340.	1.0	9
97	IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice. Diabetologia, 2008, 51, 1862-1872.	6.3	55
98	Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Molecular Cancer Therapeutics, 2008, 7, 1309-1318.	4.1	43
99	Evolution to Pathogenicity of the Parvovirus Minute Virus of Mice in Immunodeficient Mice Involves Genetic Heterogeneity at the Capsid Domain That Determines Tropism. Journal of Virology, 2008, 82, 1195-1203.	3.4	15
100	FA core complex moves to chromatin. Blood, 2008, 111, 4837-4838.	1.4	2
101	Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors. Blood, 2008, 112, 3138-3147.	1.4	24
102	In vivo proliferation advantage of genetically corrected hematopoietic stem cells in a mouse model of Fanconi anemia FA-D1. Blood, 2008, 112, 4853-4861.	1.4	23
103	A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. Journal of Medical Genetics, 2007, 44, 241-249.	3.2	47
104	Characteristics of Lentiviral Vectors Harboring the Proximal Promoter of the vav Proto-oncogene: A Weak and Efficient Promoter for Gene Therapy. Molecular Therapy, 2007, 15, 1487-1494.	8.2	21
105	In VitroandIn VivoExpression of Human Erythrocyte Pyruvate Kinase in Erythroid Cells: A Gene Therapy Approach. Human Gene Therapy, 2007, 18, 502-514.	2.7	6
106	Hypomorphic Mutations in the Gene Encoding a Key Fanconi Anemia Protein, FANCD2, Sustain a Significant Group of FA-D2 Patients with Severe Phenotype. American Journal of Human Genetics, 2007, 80, 895-910.	6.2	115
107	Toxicity of chemicals involved in the European project A-Cute-Tox on the myeloid hematopoietic progenitors. Toxicology Letters, 2007, 172, S75-S76.	0.8	1
108	Development of Efficent Gene Therapy for the Treatment of Erythrocyte Pyruvate Kinase Deficiency.. Blood, 2007, 110, 2584-2584.	1.4	1

#	Article	IF	Citations
109	Relationship between the Hematopoietic Phenotype and the Subtype of Fanconi Anemia Mice.. Blood, 2007, 110, 2447-2447.	1.4	0
110	A Simplified Approach to Improve the Efficiency and Safety ofEx VivoHematopoietic Gene Therapy in Fanconi Anemia Patients. Human Gene Therapy, 2006, 17, 245-250.	2.7	18
111	Role of the in vitro hematopoietic cultures in the European Project A-Cute-Tox. Toxicology Letters, 2006, 164, S204-S205.	0.8	0
112	The mobilization of hematopoietic progenitors to peripheral blood is predictive of the hematopoietic syndrome after total or partial body irradiation of mice. International Journal of Radiation Oncology Biology Physics, 2006, 64, 612-618.	0.8	16
113	Adipose Tissueâ€Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graftâ€Versusâ€Host Disease. Stem Cells, 2006, 24, 2582-2591.	3.2	649
114	Hematopoietic mobilization in mice increases the presence of bone marrow-derived hepatocytes viain vivocell fusion. Hepatology, 2006, 43, 108-116.	7.3	120
115	Functional analysis of gammaretroviral vector transduction by quantitative PCR. Journal of Gene Medicine, 2006, 8, 1097-1104.	2.8	10
116	Lentiviral vector integration sites in human NOD/SCID repopulating cells. Journal of Gene Medicine, 2006, 8, 1197-1207.	2.8	46
117	Hematopoietic Dysfunction in a Mouse Model for Fanconi Anemia Group D1. Molecular Therapy, 2006, 14, 525-535.	8.2	101
118	Clinical Characteristics of Patients with Fanconi Anemia in Complementation Group J.. Blood, 2006, 108, 3769-3769.	1.4	3
119	A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood, 2005, 105, 1946-1949.	1.4	89
120	Engraftment kinetics of human CD34+ cells from cord blood and mobilized peripheral blood co-transplanted into NOD/SCID mice. Bone Marrow Transplantation, 2005, 35, 271-275.	2.4	8
121	Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Therapy, 2005, 12, 341-349.	4.6	46
122	Efficient engraftment of in utero transplanted mice with retrovirally transduced hematopoietic stem cells. Gene Therapy, 2005, 12, 358-363.	4.5	13
123	Non-homologous End-Joining Defect in Fanconi Anemia Hematopoietic Cells Exposed to Ionizing Radiation. Radiation Research, 2005, 164, 635-641.	1.5	13
124	In Vitro and In Vivo Immunomodulatory Effects of Mesenchymal Stem Cells from Adipose Tissue.. Blood, 2005, 106, 3098-3098.	1.4	3
125	Quantitative PCR analysis reveals a high incidence of large intragenic deletions in the FANCA gene in Spanish Fanconi anemia patients. Cytogenetic and Genome Research, 2004, 104, 341-345.	1.1	21
126	Functional and phenotypic variations in human T cells subjected to retroviral-mediated gene transfer. Gene Therapy, 2004, 11, 474-482.	4.5	10

#	Article	IF	Citations
127	Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice. Experimental Hematology, 2004, 32, 360-364.	0.4	25
128	A New Approach to Evaluate the Total Reserve of Hematopoietic Progenitors after Acute Irradiation. Radiation Research, 2004, 162, 397-404.	1.5	9
129	Jun N-terminal kinase activity and early growth-response factor-1 gene expression are down-regulated in Fanconi anemia group A lymphoblasts. Blood, 2004, 103, 128-132.	1.4	7
130	Gene Therapy of the Human Erythrocyte Pyruvate Kinase Deficiency.. Blood, 2004, 104, 1635-1635.	1.4	0
131	Retroviral Gene Transfer of Suicide Genes in Human T Lymphocytes: Improved Transduction Conditions for a Clinical Protocol.. Blood, 2004, 104, 5247-5247.	1.4	0
132	Genetic modification of hematopoietic stem cells: recent advances in the gene therapy of inherited diseases. Archives of Medical Research, 2003, 34, 589-599.	3.3	2
133	In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Experimental Hematology, 2003, 31, 1104-1111.	0.4	16
134	Transplantation of marrow cells from children with standard risk-acute lymphoblastic leukemia at the end of therapy into NOD/SCID mice for detecting residual leukemic cells with in vivo growth potential. Leukemia Research, 2003, 27, 1153-1157.	0.8	3
135	Purging of leukemia-contaminated bone marrow grafts using suicide adenoviral vectors: an in vivo murine experimental model. Gene Therapy, 2003, 10, 1328-1335.	4.5	7
136	Safety of retroviral gene marking with a truncated NGF receptor. Nature Medicine, 2003, 9, 367-369.	30.7	169
137	Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelisâ„¢ (ET-743). Toxicology in Vitro, 2003, 17, 671-674.	2.4	11
138	Application of the CFU-GM Assay to Predict Acute Drug-Induced Neutropenia: An International Blind Trial to Validate a Prediction Model for the Maximum Tolerated Dose (MTD) of Myelosuppressive Xenobiotics. Toxicological Sciences, 2003, 75, 355-367.	3.1	128
139	Parvovirus Infection Suppresses Long-Term Repopulating Hematopoietic Stem Cells. Journal of Virology, 2003, 77, 8495-8503.	3.4	24
140	In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. European Journal of Cancer, 2002, 38, 1395-1404.	2.8	30
141	In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood, 2002, 100, 2032-2039.	1.4	62
142	In Vitro Tests for Haematotoxicity: Prediction of Drug-induced Myelosuppression by the CFU-GM Assay. ATLA Alternatives To Laboratory Animals, 2002, 30, 75-79.	1.0	18
143	In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood, 2002, 100, 2032-2039.	1.4	2
144	In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood, 2002, 100, 2032-9.	1.4	23

#	Article	IF	Citations
145	In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells. Toxicology in Vitro, 2001, 15, 347-350.	2.4	11
146	Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicology in Vitro, 2001, 15, 729-740.	2.4	112
147	Ex vivo expansion of umbilical cord blood (UCB) CD34+ cells alters the expression and function of Î±4Î²1 and Î±5Î²1 integrins. British Journal of Haematology, 2001, 115, 213-221.	2.5	28
148	Systematic analysis of clinically applicable conditions leading to a high efficiency of transduction and transgene expression in human T cells. Journal of Gene Medicine, 2001, 3, 32-41.	2.8	8
149	Latent hematopoietic stem cell toxicity associated with protracted drug administration. Experimental Hematology, 2001, 29, 286-294.	0.4	10
150	In vitro and in vivo susceptibility of mouse megakaryocytic progenitors to strain i of parvovirus minute virus of mice. Experimental Hematology, 2001, 29, 1303-1309.	0.4	17
151	A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptinâ€targeted keratinocyte grafts. FASEB Journal, 2001, 15, 1529-1538.	0.5	68
152	Selective Transduction of Murine Myelomonocytic Leukemia Cells (WEHI-3B) with Regular and RGD-Adenoviral Vectors. Molecular Therapy, 2001, 3, 70-77.	8.2	22
153	Transplantation of syngenic bone marrow contaminated with NGFr-marked WEHI-3B cells: an improved model of leukemia relapse in mice. Leukemia, 2000, 14, 457-465.	7.2	6
154	Lymphohematopoietic stem cells from donor origin are preserved in bone marrow implants beneath the renal capsule of non-conditioned host mice. Experimental Hematology, 2000, 28, 128.	0.4	0
155	Residual damage of lymphohematopoietic repopulating cells after irradiation of mice at different stages of development. Experimental Hematology, 2000, 28, 87-95.	0.4	10
156	Implantation of bone marrow beneath the kidney capsule results in transfer not only of functional stroma but also of hematopoietic repopulating cells. Blood, 2000, 96, 2307-2309.	1.4	16
157	Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice. Blood, 2000, 95, 2312-2320.	1.4	85
158	Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice. Blood, 2000, 95, 2312-2320.	1.4	3
159	Implantation of bone marrow beneath the kidney capsule results in transfer not only of functional stroma but also of hematopoietic repopulating cells. Blood, 2000, 96, 2307-2309.	1.4	0
160	Conclusions of a national multicenter intercomparative study of in vitro cultures of human hematopoietic progenitors. Bone Marrow Transplantation, 1999, 23, 373-380.	2.4	17
161	PRESERVED LONG-TERM REPOPULATION AND DIFFERENTIATION PROPERTIES OF HEMATOPOIETIC GRAFTS SUBJECTED TO EX VIVO EXPANSION WITH STEM CELL FACTOR AND INTERLEUKIN 111. Transplantation, 1999, 67, 1348-1357.	1.0	31
162	Severe Leukopenia and Dysregulated Erythropoiesis in SCID Mice Persistently Infected with the Parvovirus Minute Virus of Mice. Journal of Virology, 1999, 73, 1774-1784.	3.4	51

#	Article	IF	Citations
163	AM218, a new polyanionic polysaccharide, induces radioprotection in mice when administered shortly before irradiation. International Journal of Radiation Biology, 1997, 71, 101-108.	1.8	8
164	Does the Granulocyte-Macrophage Colony-Forming Unit Content in Ex Vivoâ€“Expanded Grafts Predict the Recovery of the Recipient Leukocytes?. Blood, 1997, 90, 464-470.	1.4	17
165	Does the Granulocyte-Macrophage Colony-Forming Unit Content in Ex Vivoâ€“Expanded Grafts Predict the Recovery of the Recipient Leukocytes?. Blood, 1997, 90, 464-470.	1.4	2
166	The Use of In Vitro Systems for Evaluating Haematotoxicity. ATLA Alternatives To Laboratory Animals, 1996, 24, 211-231.	1.0	50
167	AM5, a proteinâ€associated polysaccharide, stimulates hematopoiesis and modulates the expression of endogenous hematopoietic growth factors in murine longâ€term bone marrow cultures. Stem Cells, 1995, 13, 175-185.	3.2	4
168	Analysis of Hematopoiesis in Mice Irradiated with 500 mGy of X Rays at Different Stages of Development. Radiation Research, 1995, 143, 327.	1.5	19
169	Myeloid depression follows infection of susceptible newborn mice with the parvovirus minute virus of mice (strain i). Journal of Virology, 1995, 69, 3229-3232.	3.4	33
170	Ex vivo expansion and selection of retrovirally transduced bone marrow: an efficient methodology for gene-transfer to murine lympho-haemopoietic stem cells. British Journal of Haematology, 1994, 87, 6-17.	2.5	33
171	Residual Haematopoietic Damage in Adult and 8 Day-old Mice Exposed to 7 Gy of X-rays. International Journal of Radiation Biology, 1993, 63, 59-67.	1.8	11
172	Radioprotection Mediated by the Haemopoietic Stimulation Conferred by AM5: A Protein-associated Polysaccharide. International Journal of Radiation Biology, 1992, 62, 65-72.	1.8	21
173	Mechanisms towards compensation of long-term haemopoietic injury in mice after 5 Gy irradiation: In vivo and in vitro enhancement of superoxide anion production by granulocytes. Bioscience Reports, 1992, 12, 281-292.	2.4	6
174	Cytotoxic Infection of Hematopoietic Stem and Committed Progenitor Cells by the Parvovirus Minute Virus of Mice Propagation of an Acute Myelosuppression in Culture. Annals of the New York Academy of Sciences, 1991, 628, 262-272.	3.8	3
175	Kinetic studies of pyruvate kinase during in vitro differentiation of GM-CFC haemopoietic precursor and bone marrow cells in mice. Bioscience Reports, 1990, 10, 141-154.	2.4	3
176	Production of Humoral Factors That Stimulate Spleen Colony-Forming Units in Mice Irradiated with Moderate Doses of X Rays. Radiation Research, 1990, 122, 53.	1.5	5
177	Pyruvate kinase during in vitro differentiation of GM-CFC haemopoietic precursor in mice: modulation by l-alanine and l-phenylalanine. Biochimie, 1989, 71, 763-766.	2.6	3
178	Differential sensitivity to hyperthermia of mouse normal haemopoietic stem cells related to proliferation activity and organ source. International Journal of Hyperthermia, 1987, 3, 365-377.	2.5	9